Log in
Enquire now
‌

US Patent 11767309 Methods of synthesizing substituted pyridinone-pyridinyl compounds

Patent 11767309 was granted and assigned to Aclaris Therapeutics on September, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Aclaris Therapeutics
Aclaris Therapeutics
Current Assignee
Aclaris Therapeutics
Aclaris Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11767309
Patent Inventor Names
Gary A. Decrescenzo
John Robert Springer
Date of Patent
September 26, 2023
Patent Application Number
17533931
Date Filed
November 23, 2021
Patent Primary Examiner
‌
Brandon J Fetterolf
CPC Code
‌
C07D 405/12
‌
C07D 401/14
‌
C07D 401/04
Patent abstract

The present disclosure provides methods of synthesizing a compound of Formula (P)-I. The method proceeds through several different pathways including several novel chiral separations, a Sonogashira coupling, a zinc mediated reductive cyanation, as well as through various halide containing intermediates. Also disclosed is the multi-kilogram preparation of several novel intermediates.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11767309 Methods of synthesizing substituted pyridinone-pyridinyl compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.